Log in
Enquire now
‌

US Patent 9975935 NEIL3 peptides and vaccines including the same

Patent 9975935 was granted and assigned to OncoTherapy Science, Inc. on May, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
OncoTherapy Science, Inc.
OncoTherapy Science, Inc.
0
Current Assignee
OncoTherapy Science, Inc.
OncoTherapy Science, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
99759350
Patent Inventor Names
Takuya Tsunoda0
Yusuke Nakamura0
Yoichi Furukawa0
Ryuji Ohsawa0
Sachiko Yoshimura0
Tomohisa Watanabe0
Date of Patent
May 22, 2018
0
Patent Application Number
152287850
Date Filed
August 4, 2016
0
Patent Primary Examiner
‌
Sheela J. Huff
0
Patent abstract

The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9975935 NEIL3 peptides and vaccines including the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.